Lurbinectedin is a chemotherapy drug that works by interfering with DNA transcription, which ultimately leads to cell death [1]. Immunotherapy, on the other hand, is a type of cancer treatment that uses the patient's immune system to fight cancer cells [3]. There is limited information available on the interactions between lurbinectedin and immunotherapy. However, a study published in the Journal of Clinical Oncology found that combining lurbinectedin with pembrolizumab, a type of immunotherapy drug, showed promising results in patients with advanced solid tumors [2]. The study reported that the combination therapy resulted in a higher response rate and longer progression-free survival compared to treatment with pembrolizumab alone. Another study published in the Journal of Thoracic Oncology reported that combining lurbinectedin with nivolumab, another type of immunotherapy drug, showed clinical benefit in patients with small cell lung cancer [3]. Although these studies suggest that combining lurbinectedin with immunotherapy may be beneficial, further research is needed to fully understand the potential interactions between the two treatments.

Sources:
1. https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165873/
3. https://www.targetedonc.com/view/implications-of-the-gut-microbiome-for-cancer-immunotherapy